Cantabilin 300mg Hymecromone Biliary Therapy 40 Coated Tablets

NAME
CANTABILIN 30 MG COATED TABLETS

PHARMACOTHERAPEUTIC CATEGORY
Biliary therapies.

ACTIVE PRINCIPLES
One coated tablet contains 300 mg imecromone.

EXCIPIENTS
Corn starch, microcrystalline cellulose, gum arabic, precipitated silica, magnesium stearate, talc, dextrin, carnauba wax, sucrose, liquid glucose, erythrosine (E 127), sunset yellow (E 110).

INDICATIONS
Biliary dyskinesias. Dyspepsia secondary to insufficient biligenetic function. Spasm of the sphincter of Oddi and biliary tract. Adjuvant in gallbladder lithiasis, cholecystitis and after-effects of cholecystectomy. Adjuvant in small and medium hepatic insufficiency.

CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity 'to the active substance or to any of the excipients.

DOSAGE
1-2 coated tablets 2-3 times a day.

STORAGE
This medicinal product does not require any special storage conditions.

WARNINGS
Do not use in case of obstruction of the bile ducts and in case of severe hepatic insufficiency. The medicine contains sunset yellow, an azo dye which may cause allergic reactions. Patients with rare glucose-galactose malabsorption problems should not take this medicine.

INTERACTIONS
The extensive use of the product did not reveal particular interactions with other drugs.

SIDE EFFECTS
Within each frequency class, undesirable effects are reported in decreasing order of severity. The frequency is defined as: very common> = 1/10, common> = 1/100, uncommon> = 1 / .1000e <1/100; rare> = 1 / 10,000 and <1 / 1,000; very rare <1 / 10,000; not known. Gastrointestinal disorders. Common: diarrhea. Disorders of the immune system. Not Known: Anaphylactic reactions, including urticaria, pruritus, dyspnoea, Quicke's edema and hypotension which may progress to anaphylactic shock. Report any suspected adverse reactions via the national reporting system.

PREGNANCY AND BREASTFEEDING
Data from use in pregnant women are not available. Animal studies do not indicate teratogenic effects. As a precautionary measure, it is preferable to avoid use during pregnancy. It is not known whether imecromone or its metabolites are excreted in human milk.